Triple-Negative Breast Cancer: Genetic Vulnerabilities and Emerging Targets for Precision Oncology

Dear Colleagues,

Triple-negative breast Cancer (TNBC) is a highly aggressive and heterogeneous subtype of breast cancer characterized by the absence of estrogen and progesterone receptors and HER2 amplification. This biological profile is associated with poor prognosis, high recurrence rates, and limited therapeutic options. Recent advances in large-scale techniques, like genomics, epigenomics, transcriptomics, and tumor immunology knowledge, have uncovered multiple genetic vulnerabilities and molecular mechanisms that drive TNBC progression and resistance to therapy. In parallel, emerging precision oncology strategies include immune checkpoint inhibitors and novel targeted agents, which have shown promising results in some patients, supporting the importance of personalized approaches in TNBC treatment. This Topic aims to compile original research, comprehensive reviews, and case studies focused on the biological mechanisms and clinical management strategies of TNBC. The scope includes the following: Genetic and epigenetic alterations in TNBC Identification and validation of novel biomarkers; Multi-omics integration and subtype classification; Mechanisms of therapeutic resistance; Immune microenvironment and immunotherapy; Novel drug targets and preclinical models; Population-based studies and Disparities in TNBC outcomes. We welcome multidisciplinary contributions from molecular biology, bioinformatics, pharmacology, oncology, pathology, and public health to foster collaboration and innovation in tackling TNBC's unique challenges.

Dr. Tatiana de Almeida Simão
Dr. Sheila Coelho Soares-Lima
Topic Editors